Wayland Group Corp. Stock Canadian Securities Exchange
Equities
WAYL
CA9442041062
Pharmaceuticals
Sales 2016 | 4.06 5.55 | Sales 2017 | 3.22 4.4 | Capitalization | 203M 278M |
---|---|---|---|---|---|
Net income 2016 | -8M -10.93M | Net income 2017 | -67M -91.52M | EV / Sales 2016 * | - |
Net Debt 2016 | 9.13 12.47 | Net cash position 2017 | 0.42 0.57 | EV / Sales 2017 | 63,046,727 x |
P/E ratio 2016 * |
-
| P/E ratio 2017 |
-2.13
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
1st Jan change | Capi. | |
---|---|---|
+44.36% | 6.29B | |
-13.52% | 4.55B | |
+10.85% | 3.27B | |
-6.52% | 3.23B | |
-0.71% | 2.56B | |
+51.14% | 2B | |
-5.22% | 1.68B | |
+1.29% | 1.64B | |
+57.69% | 1.6B |